PULMONX CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.575 USD | +1.00% |
|
+1.95% | -40.59% |
| Apr. 02 | Pulmonx Appoints Mehul Joshi as Chief Financial Officer | MT |
| Apr. 02 | Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024 | CI |
Financials (USD)
| Sales 2024 * | 82.18M | Sales 2025 * | 97.46M | Capitalization | 291M |
|---|---|---|---|---|---|
| Net income 2024 * | -71M | Net income 2025 * | -64M | EV / Sales 2024 * | 3.54 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.99 x |
| P/E ratio 2024 * |
-4.06
x | P/E ratio 2025 * |
-4.58
x | Employees | 279 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pulmonx Corporation
More recommendations
More press releases
More news
| 1 day | +1.00% | ||
| 1 week | +1.95% | ||
| Current month | -18.28% | ||
| 1 month | -15.17% | ||
| 3 months | -42.53% | ||
| 6 months | -14.21% | ||
| Current year | -40.59% |
1 week
7.21
7.76
1 month
7.219.46
Current year
7.2114.84
1 year
7.2114.84
3 years
4.0748.77
5 years
4.0769.48
10 years
4.0769.48
| Managers | Title | Age | Since |
|---|---|---|---|
Ryan Olivera
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Tech/Sci/R&D Officer | - | 07-12-31 | |
Lauren Cristina
ADM | Chief Administrative Officer | - | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Ferrari
BRD | Director/Board Member | 70 | 07-01-31 |
Glendon French
BRD | Director/Board Member | 62 | 14-12-17 |
Dana Mead
CHM | Chairman | 64 | 10-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 7.575 | +1.00% | 79 522 |
| 24-04-23 | 7.5 | +1.35% | 235,799 |
| 24-04-22 | 7.4 | -1.46% | 236,579 |
| 24-04-19 | 7.51 | +0.13% | 347,792 |
| 24-04-18 | 7.5 | +0.94% | 542,149 |
Delayed Quote Nasdaq, April 24, 2024 at 11:46 am EDT
More quotes
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.5
USD
Average target price
16.2
USD
Spread / Average Target
+116.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.59% | 291M | |
| +72.28% | 12.32B | |
| -17.80% | 7.96B | |
| +3.57% | 5.84B | |
| +6.65% | 5.11B | |
| +20.83% | 4.28B | |
| -19.84% | 4B | |
| -40.77% | 2.15B | |
| +0.25% | 2.01B | |
| +4.02% | 1.8B |
- Stock Market
- Equities
- LUNG Stock
